EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSBSLG00000000359
Gene Symbol: LOC114851185
2 Cross references
292 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSBSLG00000008493
Gene Symbol: LOC114844511
3 Cross references
205 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSBSLG00000018188
Gene Symbol: LOC114869515
3 Cross references
197 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSBSLG00000005737
Gene Symbol: LOC114848551
3 Cross references
215 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSBSLG00000002674
Gene Symbol: LOC114868473
2 Cross references
230 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSBSLG00000021810
Gene Symbol: LOC114844898
3 Cross references
229 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSBSLG00000013353
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSBSLG00000007550
Gene Symbol: SLC29A1
3 Cross references
207 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSBSLG00000022608
Gene Symbol: SLC29A1
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSBSLG00000009330
Gene Symbol: SLC5A2
3 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSBSLG00000010137
Gene Symbol: SLC6A1
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSBSLG00000024700
Gene Symbol: SLC6A2
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).